PGE₂ Production after Angiotensin-Converting Enzyme Inhibition

References

• Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15(Suppl 5)S65–S72
   PubMed Web of Science ®Google Scholar
• Anonymous. Atherosclerosis goes to the wall. Lancet 1992; 339: 647–648
   PubMed Web of Science ®Google Scholar
• Bennett A, Berstock D A, Carroll M A. Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy. Br J Cancer 1982; 45: 762–768
   PubMed Web of Science ®Google Scholar
• Berliner J A, Navab M, Fogelman A M, et al. Atherosclerosis: Basic Mechanisms Oxidation, Inflammation, and Genetics. Circulation 1995; 91: 2488–2496
   PubMed Web of Science ®Google Scholar
• Campistol J M, Galofre J, Botey A, Torras A, Revert L I. Reversible membranous nephritis associated with diclofenac. Nephrol Dial Transplant 1989; 4: 393–395
   PubMed Web of Science ®Google Scholar
• Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes. Biochem J 1993; 290: 33–40
   PubMed Web of Science ®Google Scholar
• Deepe G S, Jr., Taylor C L, Srivastava L, Bullock W E. Impairment of granulomatous inflammatory response to Histoplasma capsulatum by inhibitors of angiotensin-converting enzyme. Infect Immun 1985; 48: 395–401
   PubMed Web of Science ®Google Scholar
• Delfraissy J-F, Galanaud P, Balavoine J-F, Wallon C, Dormont J. Captopril and immune regulation. Kidney Int 1984; 25: 925–929
   PubMed Web of Science ®Google Scholar
• Duchin K L, McKinstry D N, Cohen A I, Migdalof B H. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin Pharmaco-kinet 1988; 14: 241–259
   PubMed Web of Science ®Google Scholar
• Farhy R D, Ho K-L, Carretero O A, Scicli A G. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 1992; 182: 283–288
   PubMed Web of Science ®Google Scholar
• Ferreira S H, Vane J R. The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmac Chemother 1967; 30: 417–424
   PubMed Web of Science ®Google Scholar
• Goodwin J S, Bankhurst A D, Messner R P. Suppression of human T-cell mitogenesis by prostaglandin. J Exp Med 1977; 146: 1719–1734
   PubMed Web of Science ®Google Scholar
• Grbic J T, Mannick J A, Gough D B, Rodrick M L. The role of prostaglandin E2 in immune suppression following injury. Ann Surg 1991; 214: 253–262
   PubMed Web of Science ®Google Scholar
• Herlitz H, Svalander C, Tarkowski A, Westberg G. Influence of antihypertensive treatment on renal and extrarenal lupus manifestations in MRL/1 mice. Scand J Urol Nephrol 1988; 108: S65–S70
   Google Scholar
• Herlitz H, Edenö C, Mulec H, Westberg G, Aurell M. Captopril treatment of hypertension and renal failure in systemic lupus erythematosus. Nephron 1984; 38: 253–256
   PubMed Web of Science ®Google Scholar
• Hock F J, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991; 102: 769–773
   PubMed Web of Science ®Google Scholar
• Hvidberg E, Lausen H H, Jansen J A. Indomethacin: Plasma concentrations and protein binding in man. Eur J Clin Pharmacol 1972; 4: 119–124
   PubMed Web of Science ®Google Scholar
• Imboden J B, Stobo J D. Transmembrane signalling by the T cell antigen receptor. J Exp Med 1985; 161: 446–456
   PubMed Web of Science ®Google Scholar
• Johnsen S A, Aurell M. Immunosuppressive action of captopril blocked by prostaglandin synthetase inhibitor. Lancet 1981; 1: 1005
   PubMed Web of Science ®Google Scholar
• Kurland J I, Bockman R. Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages. J Exp Med 1978; 147: 952–957
   PubMed Web of Science ®Google Scholar
• Ling B N, Bourke E, Campbell W G, Jr., Delaney V B. Naproxen-induced nephropathy in systemic lupus erythematosus. Nephron 1990; 54: 249–255
   PubMed Web of Science ®Google Scholar
• Martin M FR, McKenna F, Bird H A, et al. A new treatment for rheumatoid arthritis?. Lancet 1984; 1: 1325–1328
   PubMed Web of Science ®Google Scholar
• Mertens W C, Bramwell V HC, Gwadry-Sridhar F, Romano W, Banerjee D, Lala P K. Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2. Lancet 1992; 340: 397–398
   PubMed Web of Science ®Google Scholar
• Motulsky H J, Smith D, Terman B I, Feldman R. Regulation of hormone-stimulated cyclic AMP accumulation in intact human mononuclear leukocytes by blood plasma. J Cyclic Nucleotide Protein Phosphor Res 1987; 11: 329–343
   Google Scholar
• Nishimura H, Kubo S, Ueyama M, Kubota J, Kawamura K. Peripheral hemodynamic effects of captopril in patients with congestive heart failure. Am Heart J 1989; 117: 100–105
   PubMed Web of Science ®Google Scholar
• Olausson M, Mjörnstedt L, Wrammer L, Herlitz H. Effect of captopril treatment on allograft survival and induction of unresponsiveness in heart-transplanted, ATG-treated rats. Nephrol Dial Transplant 1992; 7: 1130–1132
   PubMed Web of Science ®Google Scholar
• Ondetti M A, Williams N J, Sabo E F, Pluscec J, Weaver E R, Kocy O. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca, Isolation, elucidation of structures and synthesis. Biochemistry 1971; 19: 4033–4039
   Google Scholar
• Orlandi M, Bartolini G, Chiricolo M, Minghetti L, Franceschi C, Tomasi V. Prostaglandin and Thromboxane biosynthesis in isolated platelet-free human monocytes. Prostaglandins Leukot Med 1985; 18: 205–216
   PubMedGoogle Scholar
• Papadogiannakis N, Johnsen S A, Olding L B. A prosta-glandin-mediated suppressive activity of cord as compared to maternal or other adult adherent cells in OKT3 antibody-induced proliferation. Cell Immunol 1986; 101: 51–61
   PubMed Web of Science ®Google Scholar
• Proud D. Kinin information: Mechanisms and role in inflammatory disorders. Ann Rev Immunol 1988; 6: 49–83
   PubMed Web of Science ®Google Scholar
• Schrier D J, Ripani L M, Katzenstein A-L, Moore V L. Role of angiotensin-converting enzyme in Bacille Calmette-Guérin-induced granulomatous inflammation. J Clin Invest 1982; 69: 651–657
   PubMed Web of Science ®Google Scholar
• Shasha S M, Nusam D, Labin L, et al. Effect of converting enzyme inhibitor captopril on T cell functions in essential hypertension. Nephron 1991; 59: 586–590
   PubMed Web of Science ®Google Scholar
• Snyder D S, Beller D I, Unanue E R. Prostaglandins modulate macrophage la expression. Nature 1982; 299: 163–165
   PubMed Web of Science ®Google Scholar
• Sweet C S, Ulm E H. Enalapril. New Drugs Annual: Cardiovascular drugs, A Scriabine. Raven Press, New York 1984; 2: 1–17
   Google Scholar
• Tarkowski A, Carlsten H, Herlitz H, Westberg G. Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease. Agents Actions 1990; 31: 96–101
   PubMedGoogle Scholar
• Tilden A B, Balch C M. Indomethacin enhancement of immunocompetence in melanoma patients. Surgery 1981; 90: 77–84
   PubMed Web of Science ®Google Scholar
• Van Wauwe J, Goossens J. Mitogenic actions of ortho-clone OKT3 on human peripheral blood lymphocytes: Effects of monocytes and serum components. Int J Immunopharmacol 1981; 3: 203–208
   PubMed Web of Science ®Google Scholar
• Weinstock J V, Ehrinpreis M N, Boros D L, Gee J B. Effect of SQ 14225, an inhibitor of angiotensin I-converting enzyme, on the granulomatous response to Schistosoma mansoni eggs in mice. J Clin Invest 1981; 67: 931–936
   PubMed Web of Science ®Google Scholar